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Objective. Churg-Strauss syndrome (CSS) is a
rare form of systemic vasculitis. Previous studies show-
ing cardiac involvement in CSS patients were limited in
the number of patients and were often based solely on
clinical manifestations. The aim of the present study
was to determine in detail the incidence of cardiac
involvement in a large population of ambulatory CSS
patients.
Methods. Thirty-two consecutive patients with
CSS in remission (mean  SD duration of disease
between diagnosis and enrollment 6.1  5.8 years,
mean  SD age 61  10 years) who were previously
unaware of cardiac involvement were compared with 32
randomly selected age- and sex-matched control sub-
jects, using clinical evaluation, electrocardiography
(EKG), echocardiography, and cardiac magnetic reso-
nance imaging (MRI).
Results. Detailed cardiac evaluation revealed a
62% prevalence of cardiac involvement in CSS patients
compared with 3% in controls (P < 0.001), with clinical
symptoms in 26% and 3%, respectively (P  0.009),
EKG abnormalities in 66% and 3%, respectively (P <
0.001), and echocardiographic defects in 50% and 3%,
respectively (P < 0.001). Cardiac MRI detected cardiac
manifestations in 62% of CSS patients. In the presence
of cardiac MRI abnormalities, echocardiography could
detect cardiac involvement with a sensitivity of 83% and
a specificity of 80%. The absence of symptoms or EKG
abnormalities did not exclude cardiac involvement, be-
cause abnormalities could still be detected in 38% of
these patients at the time of echocardiography or car-
diac MRI.
Conclusion. These results demonstrate a high
incidence of cardiac involvement in CSS patients. Sys-
tematic cardiac evaluation including detailed imaging is
required to properly identify CSS patients with cardiac
involvement.
Churg-Strauss syndrome (CSS) is a rare form of
systemic vasculitis that was first described in 1951 (1).
Classically, it is characterized by extravascular granulo-
mas and necrotizing vasculitis affecting the small vessels.
Themajorclinicalmanifestationsareasthma,hypereosino-
philia, and extrapulmonary manifestations of systemic
vasculitis (2). Because of the frequent occurrence of
antineutrophil cytoplasmic antibodies (ANCAs) and
clinical and histopathologic abnormalities, CSS has been
classified along with Wegener’s granulomatosis (WG)
and microscopic polymyositis as one of the ANCA-
associated vasculitides (3). The cardiac manifestations in
CSS are highly variable, ranging from (peri)myocarditis,
heart failure, myocardial infarction, and pericardial ef-
fusion to cardiac tamponade (4–7). When these mani-
festations are present, they are associated with a worse
prognosis (6,8–12).
Considering the potential adverse outcomes as-
sociated with cardiac involvement in CSS, early detec-
tion is of clinical importance. Unfortunately, due to its
often subclinical course as a result of silent infiltration,
cardiac pathology might be underdiagnosed by clini-
cians. Until now, the described incidence of cardiac
involvement has largely varied, ranging from 17% when
using electrocardiography (EKG) only, to up to 92% in
postmortem trials (4–7,13,14). However, these studies
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lack thorough cardiac evaluation, include patients with
varying disease activity, and are based mostly on clinical
manifestations without detailed cardiac imaging. Two
previous studies assessed cardiac involvement using
echocardiography in a relatively small number of pa-
tients (15,16). In addition, systematic use of cardiac
magnetic resonance imaging (MRI) to evaluate cardiac
involvement in a population of ambulatory patients with
CSS has not previously been done, despite case reports
illustrating its possible value for early and accurate
detection of myocardial inflammation and fibrosis in
CSS patients (17–19).
Thus, the aim of this study was to shed further
light on the incidence of cardiac involvement in a popu-
lation of ambulatory patients with CSS without previous
in-depth cardiac screening. Thirty-two CSS patients
were compared with randomly selected age- and sex-
matched control subjects, using detailed outpatient car-
diac evaluation.
PATIENTS AND METHODS
CSS patients. Patients were enrolled at the Maastricht
University Hospital from August 2006 to June 2008. Ambula-
tory patients with previously diagnosed CSS who attended our
clinical immunology outpatient department were invited to
participate in this study. We included all patients who re-
sponded to the invitation and whose disease was in a clinically
stable phase. All CSS patients fulfilled the Chapel Hill Con-
sensus Conference criteria for vasculitis (20) and the American
College of Rheumatology criteria for CSS (21). Furthermore,
by using a recently developed vasculitides algorithm, all pa-
tients were classified as having CSS (22). Patients were treated
according to a standardized protocol (23). This consisted of
prednisolone (1 mg/kg body weight) daily with a maximal oral
prednisolone dosage of 60 mg/day. After 4–6 weeks, the daily
prednisolone dose was tapered by 10 mg every 2 weeks until
the dose reached 30 mg, and thereafter by 5 mg every 2–4
weeks. Cyclophosphamide (2 mg/kg body weight daily) was
added in patients with renal involvement, mononeuritis, and/or
other severe organ involvement. Once remission was achieved,
oral cyclophosphamide was stopped and replaced by azathio-
prine, or, in case of azathioprine intolerance, by mycopheno-
late mofetil maintenance therapy. In the year prior to cardiac
assessment, 24 of 32 patients (75%) were receiving mainte-
nance corticosteroid therapy, with an average dosage of 10
mg/day, and 13 of 32 patients (41%) were receiving mainte-
nance immunosuppressive therapy.
Disease activity was assessed using the Birmingham
Vasculitis Activity Score (BVAS) (24), as recommended (25).
Disease features were considered only when they were attrib-
utable to active vasculitis. All patients were seen by a vasculitis
specialist (PvP or JWCT). A detailed clinical history was
obtained, and a routine physical examination and standard
blood tests were performed. Cardiac assessment included
12-lead EKG, transthoracic echocardiography, and cardiac
MRI. Twenty-four hour Holter monitoring, coronary angiog-
raphy, or endomyocardial biopsies were performed only upon
indication, clinical symptoms, and echocardiographic and/or
cardiac MRI findings. Cardiac involvement is characterized by
conduction disturbances, pericardial effusion, myocarditis, fo-
cal myocardial fibrosis and/or edema, wall motion abnormali-
ties, significant valvular regurgitation (grade 3), or pulmo-
nary hypertension.
Control subjects. Control subjects matched for age
(mean  SD age 61  10 years) and sex (22 men) were
randomly selected from a preexisting family-based population
from a geographically similar area as part of the Flemish Study
on Environment, Genes and Health Outcomes (FLE-
MENGHO) (26). The protocol of the FLEMENGHO study
was approved by the Ethics Committee of the University of
Leuven, Leuven, Belgium. A sample was randomly selected
from a population of 480 control subjects and stratified by age
and sex. A detailed medical history had been collected previ-
ously. Subjects underwent a physical examination, routine
blood analyses, 12-lead EKG, and transthoracic echocardiog-
raphy (27).
Detection and classification of myeloperoxidase
(MPO) ANCAs. ANCAs were detected by a combination of
indirect immunofluorescence assay and enzyme-linked immu-
nosorbent assay (ELISA) for MPO ANCAs and proteinase 3
ANCAs (28). Results obtained by direct ELISA were con-
firmed by capture ELISA (28,29).
EKG. A standard resting 12-lead EKG was recorded
and analyzed by 1 experienced physician (RMD) who was
blinded to patient details. All EKGs were inspected visually to
detect technical errors, missing leads, and inadequate quality,
and findings were divided into minor and major abnormalities
(30). Criteria for minor EKG abnormalities were any of the
following: first- and second-degree atrioventricular block, pro-
longed ventricular repolarization, isolated minor Q and ST-T
abnormalities (low-amplitude T waves and abnormally in-
verted T waves), left ventricular (LV) hypertrophy without
ST-T abnormalities, and fascicular blocks. Major EKG abnor-
malities were defined by the following: high-degree atrioven-
tricular dissociation, left or right bundle-branch block, indeter-
minate conduction delay, LV hypertrophy with ST-T
abnormalities, and presence of arrhythmias (e.g., atrial fibril-
lation, atrial flutter, supraventricular tachycardia, ventricular
tachycardia).
Transthoracic echocardiography. Echocardiographic
examinations were performed in standard parasternal, apical,
and subxiphoidal views according to the recommendations of
the American Society of Echocardiography (31), using a Sonos
5500 from Philips Medical Systems (Best, The Netherlands).
The following dimensions were measured: LV end-diastolic
diameter (EDD), LV end-systolic diameter, and end-diastolic
thickness of the septum and LV posterior wall. LV end-
diastolic volume and end-systolic volume (ESV) were obtained
from the apical 4- and 2-chamber views by the modified
Simpson’s method. The LV ejection fraction (LVEF) was
calculated in a standard manner and was used to assess global
LV systolic function. Right ventricular (RV) size and function
were evaluated qualitatively. RV systolic pressure was esti-
mated based on the modified Bernoulli equation and was
considered to be equal to the systolic pulmonary artery
pressure (sPAP) in the absence of RV outflow obstruction:
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sPAP (mm Hg)  RV systolic pressure  trans-tricuspid
gradient  right atrial pressure (RAP), where trans-tricuspid
gradient is 4v2 (v  peak velocity of tricuspid regurgitation in
meters/second). RAP was estimated based on the variation in
the size of the inferior vena cava with inspiration. Abnormal-
ities were reported as wall motion abnormalities, significant
valvular regurgitation (grade 3), pericardial effusion, pulmo-
nary hypertension (sPAP 45 mm Hg), endocardial defects,
and/or obliterated ventricles.
Cardiac MRI. Patients were examined in a supine
position with a 1.5T MR scanner (Gyroscan Intera; Philips
Medical Systems) equipped with a cardiac software package
and a dedicated phased-array surface coil. After survey scans,
EKG-gated cine images were acquired for functional analysis
during multiple breath holds using a steady-state free preces-
sion sequence in 2-chamber–long axis, 3-chamber–long axis,
4-chamber–long axis, and continuous short axis view covering
the entire left ventricle. For the detection of myocardial edema
or acute inflammation, multislice short axis images were
acquired using a dual-inversion black-blood T2-weighted se-
quence with fat suppression. A Look-Locker sequence was
then applied to determine the inversion time for the subse-
quent late enhancement scan to optimally “null” LV myocar-
dium. A breath-hold multislice T1-weighted 3-dimensional
inversion recovery gradient-echo sequence to evaluate the
presence of myocardial fibrosis was used to acquire images in
short axis, horizontal long axis, and vertical long axis orienta-
tion 10 minutes after intravenous administration of 0.2
mmoles/kg gadopentate dimeglumine with an injection rate of
3 ml/second.
MR images were analyzed with commercially available
software (CAAS MRV 3.0; Pie Medical Imaging, Maastricht,
The Netherlands, and MASS 6.0; Medis Medical Imaging
Systems, Leiden, The Netherlands) by 2 independent readers
(one of whom was SS) who were blinded to patient details.
Abnormalities were reported as wall motion abnormalities,
significant valvular regurgitation (grade 3), pericardial effu-
sion, endocardial defects, and/or obliterated ventricles. Images
were considered to show pathology if localized intramyocardial
increased signal intensity on T2-weighted images (edema)
and/or delayed contrast enhancement (focal fibrosis) was
present.
Statistical analysis. The prevalence of cardiac involve-
ment was calculated and compared between the groups. Cat-
egorical variables were assessed using the chi-square test, and
continuous variables were compared using Student’s unpaired
t-test. Correlation calculation was performed using Pearson’s
correlation coefficient. All values are presented as the mean 
SD. P values less than 0.05 were considered significant. Statis-
tical analyses were performed using SPSS version 15.0 software
(SPSS, Chicago, IL).
RESULTS
Patient data. Thirty-two consecutive CCS pa-
tients (mean  SD age 61  10 years, 22 men) and 32
Table 1. Baseline characteristics of the CSS patients and control subjects*
CSS patients
(n  32)
Control subjects
(n  32) P
Age, mean  SD years 61  10 61  10 NS
Men/women 22/10 22/10 NS
Years since diagnosis of CSS, mean  SD 6.1  5.8 NA –
BVAS, mean  SD, 0–6 0  0 NA –
Prior medical history
Hypertension 7 (22) 14 (44) NS
Dyslipidemia 6 (19) 5 (16) NS
Diabetes mellitus 4 (13) 0 (0) 0.04
Acute coronary syndrome 1 (3) 0 (0) NS
Medications at enrollment
Corticosteroids 24 (75) NA –
Immunosuppressive agents 13 (41) NA –
Beta blockers 7 (22) 6 (19) NS
Angiotensin receptor blockers or ACE inhibitors 8 (25) 1 (3) 0.01
Vital signs
Heart rate, mean  SD beats per minute 72  8 87  14 0.001
Systolic blood pressure, mean  SD mm Hg 128  18 131  15 NS
Diastolic blood pressure, mean  SD mm Hg 76 10 80  8 NS
Laboratory parameters
Serum creatinine, mean  SD mmoles/liter 117  92 87  14 NS
Total eosinophil count  106/liter, mean  SD 2.4  2.2 2.6  2.1 NS
Leukocyte count  109/liter, mean  SD 8.6  2.3 5.9  2.2 0.001
CRP level, mean  SD mg/dl 4.5  5.0 NA –
MPO ANCA positive at diagnosis 13 (41) NA –
* Except where indicated otherwise, values are the number (%) of patients or controls. CSS 
Churg-Strauss syndrome; NS  not significant; NA  not applicable; BVAS  Birmingham Vasculitis
Activity Score; ACE  angiotensin-converting enzyme; CRP  C-reactive protein; MPO ANCA 
myeloperoxidase antineutrophil cytoplasmic antibody.
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control subjects (mean SD age 61 10 years, 22 men)
were enrolled in this study. Baseline patient character-
istics are reported in Table 1. CSS patients had been
diagnosed as having CSS 6.1  5.8 years prior to
enrollment. Thirteen patients (41%) were MPO ANCA
positive at diagnosis. In patients, the time since the most
recent disease activity varied, but at the time of cardiac
assessment all patients were classified as having com-
plete remission of disease with a BVAS score of 0.
Laboratory findings at assessment revealed a C-reactive
protein (CRP) level of 4.5 5.0 mg/dl, a leukocyte count
of 8.6  2.3  109/liter, and a total eosinophil count of
2.4  2.2  106/liter, compatible with the fact that all
patients had clinical remission of disease at the time of
assessment. Most patients (75%) were receiving immu-
nosuppressive drugs (prednisolone with or without aza-
thioprine). Only a small percentage of patients received
blood pressure–lowering medication (Table 1). The car-
diovascular risk profile of both CSS patients and control
subjects is summarized in Table 1.
Cardiac evaluation. In the cohort of ambulatory
CSS patients with disease in remission, we found a
prevalence of cardiac involvement of 62% compared
with 3% (P  0.001) in randomly selected age- and
sex-matched control subjects. Cardiac evaluation re-
vealed clinical symptoms in 25% of CSS patients, major
EKG abnormalities in 13%, echocardiographic defects
in 50%, and cardiac MRI abnormalities in 62% (Tables
1–3).
EKG findings. EKG findings revealed abnormal-
ities in 21 CSS patients (66%) and in 1 control subject
(3%) (P  0.001) (Table 2). Minor abnormalities, such
as T wave abnormalities and/or pathologic Q waves,
were seen in 16 (50%) and 2 (6%), respectively, of the
CSS patients, while only 1 control subject (3%) had T
wave abnormalities. Major abnormalities in CSS patients
included atrial fibrillation in 1 patient (3%) and conduc-
tion disturbances (right or left bundle-branch block) in 2
patients (6%). Holter recording, performed in 21 pa-
tients, revealed an episode of nonsustained ventricular
tachycardia (NSVT) of 6 beats in 1 patient (3%).
Cardiac imaging. Cardiac assessment revealed
echocardiographic defects in 50% of CSS patients and
cardiac MRI abnormalities in 62%, ranging from wall
motion disturbances and focal fibrosis to an obliterated
right ventricle (Tables 2 and 3). Echocardiography de-
tected cardiac involvement with a sensitivity of 83% and
a specificity of 80% when cardiac MRI abnormalities
Table 2. Clinical findings in CSS patients and control subjects*
CSS patients
(n  32)
Control subjects
(n  32) P
Cardiac symptoms 8 (26) 1 (3) 0.009
Dyspnea (functional class II–III) 5 (16) – –
Chest pain 3 (9) 1 (3) –
Palpitations 2 (6) – –
EKG abnormalities 21 (66) 1 (3) 0.001
Minor 17 (53) 1 (3) 0.001
Major 4 (13) 0 (0) 0.04
Echocardiographic findings
LV ejection fraction, mean  SD % 54  12 66  6 0.001
LV end-diastolic diameter, mean  SD mm 50  7 51 5 NS
LV end-systolic diameter, mean  SD mm 36  9 31  4 0.01
LV mass, mean  SD grams 191  51 179  46 NS
Wall motion abnormalities 13 (41) 1 (3) 0.001
Regional 7 (22) 1 (3) 0.001
Global 6 (19) 0 (0) 0.001
Valvular abnormalities 4 (13) 0 (0) 0.04
Mitral regurgitation 2 (6) 0 (0) NS
Aortic regurgitation 1 (3) 0 (0) NS
Other 4 (13) 0 (0) 0.04
Pericardial effusion 2 (6) 0 (0) NS
Pulmonary hypertension 2 (6) 0 (0) NS
Endocardial defect 1 (3) 0 (0) NS
Obliterated RV 1 (3) 0 (0) NS
Combined no. of abnormalities on
echocardiography (no. of patients) 16 (50) 1 (3) 0.001
* Except where indicated otherwise, values are the number (%) of patients or controls. CSS 
Churg-Strauss syndrome; EKG  electrocardiographic; LV  left ventricle; NS  not significant; RV 
right ventricle.
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were present. Conversely, cardiac involvement deter-
mined at cardiac MRI showed a sensitivity of 88% and a
specificity of 72% when echocardiographic abnormali-
ties were present. When fibrosis on cardiac MRI was
excluded, the sensitivity and specificity of echocardiog-
raphy compared with cardiac MRI were similar (88%
and 81%, respectively). Fibrosis on MRI was found only
in patients who had other cardiac abnormalities both at
echocardiography and cardiac MRI. Significant correla-
tions were found when comparing cardiac MRI with
cardiac ultrasound for LVEF (R  0.86, P  0.001),
LVESV (R  0.86, P  0.001), LVEDV (R  0.87, P 
0.001), and LV mass (R  0.66, P  0.001).
Coronary angiography and histology. A coronary
angiogram was obtained in 13 patients with chest pain,
dyspnea, and cardiac abnormalities, revealing no steno-
sis in 8 of the 13 patients (62%). Three patients (23%)
had wall irregularities, and 2 patients (15%) showed a
lesion (70% stenosis) in the left anterior descending
coronary artery (Table 3). Nine patients underwent
endomyocardial biopsies. Five patients had an increase
in lymphocyte infiltration (14 CD45 T lymphocytes/
mm2) in their biopsy specimens, with associated active
lymphocytic myocarditis in 1 patient and eosinophilic
infiltrate in another. None of the biopsy specimens
showed histologic signs of active vasculitis. In the patient
with the episode of NSVT, histologic analysis also
showed increased lymphocytic infiltrate.
There was no relationship between the duration
of CSS, prior corticosteroid or immunosuppressive ther-
apy, and cardiac manifestations. Seventy-four percent of
ANCA-negative patients showed cardiac involvement,
and wall motion disturbances were the most frequent
finding in up to 64% of the patients. In contrast, cardiac
abnormalities could be detected in only 23% of ANCA-
positive patients (P  0.01).
Defects were seen at echocardiography or cardiac
MRI in 88% of patients who had clinical symptoms and
in all patients when major EKG abnormalities were
present. In the patients with clinical symptoms, the
finding of dyspnea could be clarified by reduced LV
function in 2 patients and significant valvular disease in
the other 3 patients. Two patients reported palpitations,
which were accompanied by atrial fibrillation and coro-
nary artery disease in both. Chest pains reported by 3
patients were associated with coronary artery disease in
2 patients, while 1 of the patients did not have any
cardiac abnormalities clarifying the symptoms. In the
absence of symptoms and with a normal EKG, cardiac
involvement could still be detected at echocardiography
or cardiac MRI in 38% of the patients.
There was a significantly greater prevalence of
diabetes mellitus (DM) in the CSS patients than in the
control subjects. When we excluded these DM patients
from the analyses, the results remained similar, revealing
abnormal clinical symptoms in 25% of CSS patients
compared with 3% of control subjects (P  0.01), major
EKG abnormalities in 11% of CSS patients compared
with 0% of control subjects (P  0.06), echocardio-
graphic defects in 54% of CSS patients compared with
3% of control subjects (P  0.001), and cardiac MRI
abnormalities in 69% of CSS patients.
DISCUSSION
The present study assessed cardiac involvement
in a cohort of 32 patients with clinically remissive CSS,
using a combination of clinical evaluation, EKG, echo-
cardiography, and cardiac MRI. Our findings reveal a
62% prevalence of cardiac abnormalities in CSS patients
compared with 3% in age- and sex-matched control
subjects. The high prevalence of cardiac defects was not
caused by concomitant cardiac diseases such as coronary
artery disease and/or hypertension, since the prevalence
of these diseases in our CSS patients was relatively low
and comparable with that in the control group (Table 1).
Table 3. Cardiac MRI and angiography findings in patients with
Churg-Strauss syndrome*
Cardiac MRI (n  29)
LV ejection fraction, mean  SD % 51  16
LV end-diastolic volume, mean  SD ml 168  58
LV end-systolic volume, mean  SD ml 91  66
LV mass, mean  SD grams 178  32
Fibrosis
Regional 7 (21)
Global 1 (3)
Inflammation 1 (3)
Wall motion abnormalities
Regional 7 (22)
Global 8 (25)
Valvular abnormalities
Mitral regurgitation 1 (3)
Aortic regurgitation 1 (3)
Other
Pericardial effusion 2 (7)
Endocardial defect 1 (3)
Obliterated RV 1 (3)
Combined no. of abnormalities on cardiac MRI
(no. of patients)
18 (62)
Angiography (n  13)
Normal 8 (62)
Wall irregularities 3 (23)
Significant lesion(s) 2 (15)
* Except where indicated otherwise, values are the number (%) of
patients. MRI  magnetic resonance imaging; LV  left ventricular;
RV  right ventricle.
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After exclusion of DM from the analysis, the differences
in cardiac abnormalities remained similar, suggesting
that DM was not a concomitant factor.
CSS is a disease characterized by asthma, hyper-
eosinophilia, and vasculitis. The disease can typically be
divided into 3 distinct phases (32). The initial phase of
the disease starts with asthma, allergic rhinitis, and nasal
polyposis, the second is marked by a period of peripheral
and tissue eosinophilia associated with pulmonary infil-
trates, and the third is characterized by systemic vascu-
litis. Involvement of the heart has been described in the
third phase as vasculitic lesions in myocardium and the
coronary vessels, causing (peri)myocarditis, heart fail-
ure, cardiac tamponade, myocardial infarction, or peri-
cardial effusion (4–7). Myocardial damage is caused by
vasculitis leading to coronaritis and coronary occlusion,
by the release of toxic mediators by activated eosinophils
causing direct myocardial damage (33), or by replace-
ment of the myocardium with granulomas and scar tissue
(14,34). Pulmonary hypertension secondary to concom-
itant pulmonary involvement may also induce RV dys-
function (35,36).
In general, the prognosis of CSS is good, with an
overall 10-year survival rate of 81–92% (7,11). Cardiac
involvement, however, is one of the most important
predictors of an adverse outcome, since up to 50% of
CSS-related mortality is caused by cardiac involvement
(6,11). Of the patients with myocardial involvement,
39% died during the acute phase of their disease (11).
Optimal therapy is therefore important, since Cohen et
al (37) reported that long-term treatment with adjunc-
tive immunosuppressive agents in patients with a poor
prognosis, including cardiac involvement, improved
event- and disease-free survival rates. In addition, sev-
eral studies showed resolution of myocardial manifesta-
tions after steroid and/or immunosuppressive therapy
(38–40). Thus, early diagnosis of cardiac involvement
and subsequent adjunctive therapy may prevent progres-
sion of cardiac disease.
Previous reports indicated that ANCA positivity
at the time of diagnosis was more often associated with
renal involvement, peripheral neuropathy, and biopsy-
proven vasculitis, whereas ANCA negativity was associ-
ated with heart disease and fever (10,41). Cardiac in-
volvement in our group was seen in 23% of the ANCA-
positive patients and in 74% of the ANCA-negative
patients. These results are concordant with those of the
French Vasculitis Study Group, which found an ANCA-
negative status in 62% of CSS patients, with cardiac
manifestations in 49% of those patients (41).
Development of accelerated atherosclerosis and
resultant ischemic heart disease is an important cause of
morbidity and mortality in different systemic auto-
immune diseases, including rheumatoid arthritis (RA),
systemic sclerosis, systemic vasculitis, systemic lupus
erythematosus (SLE), and primary antiphospholipid
syndrome (36,42,43). Systemic inflammation and immu-
nologic abnormalities result in accelerated atherosclero-
sis independent of classic risk factors (44–46). In addi-
tion, glucocorticoid therapy causes cardiac dysfunction
due to accelerated atherosclerosis and ischemic heart
disease but may also increase the incidence of DM and
hypertension.
In the present study, blood pressure did not differ
significantly between the CSS patients and the control
subjects, and the increased incidence of DM in the CSS
patients did not solely explain increased cardiac involve-
ment. Atherosclerosis related to cardiac involvement
was present in 15% of the CSS patients as detected by
coronary angiogram, concordant with cardiovascular
involvement in other autoimmune diseases (36,42). Di-
rect cardiac inflammation independent of atherosclero-
sis is an important cause of disease-associated cardiac
injury and dysfunction in different systemic diseases. In
our population, we found LV dysfunction in 34% of the
CSS patients compared with other systemic diseases
such as RA (5%), WG (15%), and SLE (27%) (47–49).
Therefore, we conclude that cardiac disease is seen in
systemic autoimmune diseases and particularly in CSS.
Immunosuppressive therapy, including glucocorticoid
treatment, will possibly help to prevent these harmful
episodes.
Our results underscore a high incidence of car-
diac manifestations in CSS patients during remission of
their disease. The clinical history, EKG, echocardiogra-
phy, and cardiac MRI were the most marked compo-
nents of the outpatient evaluation for the diagnosis of
cardiac involvement. In the absence of symptoms and
major EKG abnormalities, cardiac involvement could
still be detected in nearly 40% of the patients, indicating
that the absence of symptoms or the presence of a
normal EKG does not exclude cardiac involvement. We
therefore recommend that the evaluation for cardiac
involvement in patients with CSS should include not
only detailed history of cardiac symptoms and EKG, but
also imaging with echocardiography or cardiac MRI.
Since CSS with cardiac involvement has been associated
with a worse prognosis (6,8–12), early diagnosis is advo-
cated, since appropriate therapy may prevent progres-
sion of cardiac disease (37–40).
The present study is cross-sectional, and a longi-
tudinal study would have given additional information
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on symptoms present at the time of presentation or
during followup. Despite this limitation, this study re-
veals that systematic cardiac evaluation with detailed
imaging in CSS patients is required to properly identify
cardiac involvement. In the setting of a multidisciplinary
approach to CSS, including evaluation by a cardiologist,
our findings reveal a high incidence of cardiac abnor-
malities in CSS patients who previously were unaware of
the presence of such abnormalities.
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